Navigation Links
New approach for attacking lupus identified
Date:12/17/2007

NEW YORK CITY, Dec. 16, 2007 Investigators at Hospital for Special Surgery have identified two new targets for drugs aimed at controlling lupus. If companies are able to develop drugs that hone in on these targets, patients may be able to control their disease with few side effects.

The study identifies very good therapeutic targets, and what needs to be done is identify better candidate drugs, said Lionel Ivashkiv, M.D., director of Basic Research at Hospital for Special Surgery in New York City. He led the study, which was published online in Nature Immunology on December 16 and will appear in print in February.

Because abnormally high levels of interferon-alpha can lead to lupus, researchers have developed drugs that block interferon. These drugs, however, have immunosuppressive side effects that can leave patients vulnerable to various illnesses and infections, some of which can be deadly. Currently, these drugs are being tested in clinical trials. If researchers are able to develop drugs for the newly identified drug targets, patients may be able to avoid these immunosuppressive effects.

Interferons have two major functions. First, they protect against viruses and second, they regulate immune responses, strengthening immune responses and playing a role in autoimmunity. Different proteins, called STATs, mediate the two functions of IFN. STAT1 mediates the autoimmune and inflammatory functions, and STAT2 mediates the virus protection function. What we were interested in understanding is how you can regulate the balance between activating the inflammatory effects and the antiviral effects, Dr. Ivashkiv said. We thought if we could control the functions of the interferons, that would lead to new therapeutic approaches where you could block specifically some of their functions, but not others.

The investigators discovered that calcium specifically increases activation of STAT1 by interferons, and thus turned their attention to calcium. The researchers tested whether two kinase enzymes in the calcium-signaling pathway, CAMK and Pyk2, could be manipulated to control STAT1. In studies involving mice, the investigators showed that blocking these calcium-signaling pathways with a drug called KN-93 regulated the amount of STAT1, but not STAT2 activation.

What we found was that these kinases that are regulated by calcium actually regulate the strength of activation of STAT1 by the interferons, but they do not regulate the strength of activation of STAT2, said Dr. Ivashkiv. The idea was if you block these signaling pathways, would you block the STAT1 part, which controls the inflammatory/deleterious effects and preserve the antiviral part. We tested that in an animal model of lupus and we were able to show, in vivo, that you can suppress STAT1 activation by inhibiting the calcium-dependent kinases.

The researchers say that their work has identified a new therapeutic approach for attacking lupus. What the companies are trying to develop are, basically, antibodies against the interferons. The concern there is that if you block the interferon completely, patients may become very immunosuppressed and unable to handle viral infections, Dr. Ivashkiv said. Our idea is that if you block these calcium pathways, you could block the deleterious effects of the interferon, but maintain the antiviral effects.

Lupus is an autoimmune disease that can affect various parts of the body, including the skin, joints, heart, lungs, blood, kidneys and brain. Inflammation, considered the primary feature of lupus, is characterized by pain, heat, redness, swelling and loss of function. In most people, the disease affects only a few organs and symptoms are mild, but in others, the disease can cause serious and even life-threatening problems. According to the Lupus Foundation of America, an estimated 16,000 Americans develop lupus each year.


'/>"/>

Contact: Phyllis Fisher
fisherp@hss.edu
212-606-1724
Hospital for Special Surgery
Source:Eurekalert

Related biology news :

1. Layered approach may yield stronger, more successful bone implants
2. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
3. Book on weeds and invasive plants discusses how to manage them using ecological approaches
4. New thoracic imaging approach can pinpoint underlying venous problems
5. Gold nanorods shed light on new approach to fighting cancer
6. Deadlines for 2007 National Soybean Rust Symposium fast approaching
7. New approach builds better proteins inside a computer
8. Raydiance collaborates with Rutgers, MTF to develop innovative tissue processing approaches
9. Study identifies genetic risk factor for rheumatoid arthritis, lupus
10. Lupus Research Institute strategy delivers $30 million in national funding
11. Lupus gene finding prompts call for more DNA samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, ... developing a new category of therapeutics, announced today the ... SB-030 in peripheral artery disease. The trial will evaluate ... single-use therapeutic, in the reduction of restenosis following angioplasty. ... critical development milestone for SB-030," said Nathan Bachtell ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology: